Method for increasing proliferative activity of peripheral blood lymphocytes

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely immunology, and may be used for increasing proliferative activity of peripheral blood lymphocytes. That is ensured by applying a synthetic agent in a medicinal base. The synthetic agent is presented by synthetic peptides having the structure LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO and THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO, of molecular weight 1794 to 1397 Da, in the concentrations of 10-4 to 10-5 mg/ml of the medicinal base which is presented by physiologic saline to be applied once a day.

EFFECT: use of the given method enables higher proliferative activity of lymphocytes required for pathogenetic therapy of the diseases.

1 tbl

 

The invention relates to medicine, namely to Allergology and immunology, Microbiology, treatment, pharmacology, clinical pharmacology and can be used as a way of increasing the proliferative activity of peripheral blood lymphocytes.

The increase in lymphocyte proliferation is one of the essential mechanisms of pathogenetic therapy of diseases associated syndrome secondary immune deficiency. Search for substances and methods of directional gain proliferation relevant today.

A known way to increase the proliferative activity of lymphocytes with the use of a medicinal product Roncoleukin adopted for the prototype. Roncoleukin is a genetically engineered (recombinant) IL-2 (RIL-2), as deglycosylation analog of the polypeptide fragment of endogenous interleukin, one of the pharmacological effects of which is the activation of clonal proliferation of T-and b-lymphocytes. (Reference Vidal drugs in Russia". 2009 M: Attraversare 1760 S.; Gusev S.A., Kurisu C.V. clinical-immunological aspects of the use of Roncoleukin (interleukin-2) in clinical practice. - K.: The Lotus. 2004)

The disadvantage of this method include not only the limitation of the methods of administration (the inability intramuscular injection due to the formation of the deposits of postinjection abscesses) and a fairly wide range of complications, but lack of activation of lymphocyte proliferation.

Technical task claimed in the invention method is to increase the proliferative activity of peripheral blood lymphocytes.

The problem is solved in that way increase the proliferative activity of peripheral blood lymphocytes, involving the use of synthetic agents in medicinal basis, according to the invention as synthetic tools use of synthetic peptides having the structure from LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS THR PRO, and up to NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO, N.M. from 1794 until 1397 daltons, in concentrations ranging from 10-4up to 10-5mg/ml dosage basis, which use saline apply once a day.

Due to the fact that the way to increase the proliferative activity of peripheral blood lymphocytes as synthetic tools use of synthetic peptides having the structure from LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS THR PRO, and up to NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO, N.M. from 1794 until 1397 daltons, in concentrations ranging from 10-4up to 10-5mg/ml dosage basis, which use saline solution, applying once a day, increased proliferative activity of the organism in respect of peripheral blood lymphocytes.

Declare spoolable novelty in comparison with prototypes, different essential features that enhance the proliferative activity of peripheral blood lymphocytes.

The applicant is not unknown solutions with these distinctive features, which collectively achieve the specified result, he felt, therefore, that the proposed facility meets the criterion of "inventive step".

The inventive tool can be widely used in Allergology and immunology, Microbiology, treatment, pharmacology, clinical pharmacology.

Evaluation of the activity of the inventive means is as follows.

The main role of the immune response plays a lymphocyte - movable carrier of genetic information. Lymphocytes not only implement the immune response, but also take part in physiological processes that maintain homeostasis. Lymphocytes participate in the processes of inflammation and regeneration, the impact on the mitotic activity of different tissues, stimulate and regulate their growth.

When studying the functional activity of lymphocytes widespread method of blast transformation of lymphocytes. This method allows you to simulate one of the most important parts of the immune response - the response of lymphoid tissue on the immune stimulus. In cases involving suppression of immune responsive ness going down the practical reactivity, there is a rapid decrease or lack of transformation of lymphocytes in blastopore cells. Test blast transformation of lymphocytes is widely used in clinical practice to assess the functional activity of the immune system in humans.

Assessment of proliferative activity of lymphocytes was performed by flow cytometry (Handbook of Medical laboratory technology", Ed. "InterMedia", St. Petersburg, 1999, volume 2, str).

As control was used PHA (Difco, USA). A comparative evaluation of the intensity of activation of lymphocyte proliferation is presented in table 1.

The study involved samples of peptide ZP-1 with the structure LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO and peptide ZP-2, the structure of which is as follows THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO N.M. from 1794 until 1397 daltons. Peptide ZP-1 and peptide ZP-2 was used at a concentration of from 10-4up to 10-5mg/ml saline solution was applied once a day. Compare the following groups:

1. The level of spontaneous mitogenic activity of lymphocytes (% blast cells in suspension OLS without adding active substances).

2. The level of mitogenic activity, due to the optimal dose of PHA (% blast cells in suspension MNCs after incubation with standard mitogen PHA at a concentration of 10 mg/ml). According standartniy method.

3. The level is togendai activity due to the optimal dose of the prototype (% blast cells in suspension MNCs after incubation with Ronkoleykin at a concentration of 10 mg/ml).

4. The level of mitogenic activity, due to the optimal dose of the inventive peptide ZP1 (% blast cells in suspension MNCs after incubation with ZP1 in a concentration of from 10-4up to 10-5mg/ml).

5. The level of mitogenic activity, due to the optimal dose of the inventive peptide ZP2 (% blast cells in suspension MNCs after incubation with ZP2 in a concentration of from 10-4up to 10-5mg/ml). The results of the study are presented in table 1.

Table 1
No.SubstanceThe content of blast cells, %
1Spontaneous level15,65±1,3
2PHA (optimal dose)62,85±2,8
3Roncoleukin (prototype)56,62±3,1
5ZP159,55±4,1
6P2 97,35±5,4

Thus, the claimed peptides ZP-1, ZP-2 have the ability to induce blast transformation of lymphocytes in vitro, in excess of the prototype. It should be noted that the peptide ZP-2, consisting of 12 amino acids, and had a significantly higher activity compared with peptide ZP-1, consisting of 16 amino acids.

In the present method increases the proliferative activity of peripheral blood lymphocytes, due to the fact that as synthetic tools use of synthetic peptides having the structure from LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS THR PRO, and up to NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO, N.M. from 1794 until 1397 daltons, in concentrations ranging from 10-4up to 10-5mg/ml dosage basis, which use saline apply once a day.

The way to increase the proliferative activity of peripheral blood lymphocytes, involving the use of synthetic agents in medicinal basis, according to the invention, as synthetic tools use of synthetic peptides having the structure LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO, M.M. 1794 and 1397 daltons, in concentrations ranging from 10-4up to 10-5mg/ml dosage basis, which use saline apply once a day.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and poultry production. A phytomineral composition is characterised by preparing a solution of 3-4 g of sea salt in 1000 ml of purified water. The solution is heated to temperature 80-90°C, added with dried and ground everlasting, marigold, nettle, birch buds, pine buds, yarrow, laminaria in the following proportions in the solutions, g: everlasting 8-10, marigold 8-10, nettle 8-10, birch buds 8-10, pine buds 8-10, yarrow 8-10, laminaria 8-10, sea salt 3-4. The mixture is soaked in boiling-water bath and kept heated for 1-1.5 hours, cooled, squeezed out, filtered. During autumn, spring and winter, the mixture is added with Saint-John's-wort in the amount of 3-4 g. A method for using the phytomineral composition is characterised by processing a premise by the phytomineral composition in the form of fog spray small dispersion at approximately 1-1.5 ml per m3 and exposing for 5-10 minutes if counting from the spraying termination time.

EFFECT: use of the declared group of inventions provides effective reinforcement of the poultry immunity, has no side effects.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, particularly a method for preparing a biologically active preparation of a male larval bee homogenate. method for preparing the biologically active preparation involving preparing the a male larval bee homogenate, mixing the prepared homogenate and an adsorbent of mixed lactose and glucose taken in appropriate proportions, grinding and drying the adsorbed homohenate with the mixing process performed by grinding the fresh homogenate and the adsorbent; grinding and drying the adsorbed homogenate are followed by granulating in a propolis spirit solution in the certain environment. The biologically active preparation prepared by the declared method containing male larval bees, propolis, the adsorbent wherein the ingredients are taken in specific proportions.

EFFECT: method provides preparing the preparation showing higher biological activity and stable properties.

3 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses compositions for inducing an immune response in a patient, containing a combination of two or more monovalent conjugates wherein each of the monovalent conjugates contains a carrier protein N19 conjugated with a saccharide antigen of the serogroups A, C, W135 or Y Neissera meningitides. A molecule of the carrier protein in the monovalent conjugate is preferred to be conjugated with more than one molecule of the saccharide antigen. Besides, the invention discloses a multivalent conjugate for inducing an immune response in a patient, containing two or more antigen-different saccharide antigens of the serogroups A, C, W135 or Y Neissera meningitides conjugated with the carrier protein N19. The compositions may contain one or more said monovalent conjugates and one or more said multivalent conjugates. The invention shows applicability of the multivalent conjugate and compositions in preparing a medicine for enhancing the immune response in a patient.

EFFECT: compositions used under the invention elicit much stronger and fast immune response and exhibit lower reactogenicity for a patient.

16 cl, 33 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely otorhinolaryngology, physiotherapy, restorative and rehabilitation medicine, and may be used in acute sinusitis. A method involves exposure to bipolar symmetric fluctuating current. At first, the exposure covers a projection of an affected maxillary sinus and a pretragal region from both sides. Then the exposure covers an endonasal region and a posterior surface of a cervical spine. The current intensity is adjusted to slight vibration under the electrodes within 0.1 to 5 mA. The exposure length is 7-10 minutes. The therapeutic course is 5-7 daily procedures. The exposure procedures are followed by applications of the Tomed-applicate preparation coating a collar region at temperature 38°-40°, and then a submandibular region at temperature 22°-24°. The length of one procedure makes 15-20 minutes. The therapeutic course is 5-7 procedures.

EFFECT: invention provides higher clinical effectiveness ensured by the integrated anti-inflammatory, bacteriostatic, detoxicative, desensitising and immunostimulating effect with preventing a complication of connective tissue growth.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. A method involves collection and homogenisation of drone larvae. Before the homogenization, drone larvae are frozen at temperature (-4; -5°C) for 12-14 hours, then thawed for 3-5 minutes to +18°C and packaged. Additionally, before the homogenisation and after the first freezing and thawing, the second freezing follows at temperature (-18)-(-20)°C for 60-72 hours accompanied by thawing at room temperature, drying at warm air flow at temperature (+55)-(+60)°C to remove liquid from a larva surface completely, to dry completely and sterilise at temperature (+80)-(+85)°C for 3.5-4.0 hours. Dry drone larvae are homogenised for 1-2 minutes, then packaged in vacuum packings. The prepared drone larva powder is added with a tylosin powder and a dimetridazole powder in the following proportions, g/kg. tylosin powder - 0.090-0.100, dimetridazole powder - 0.200-0.225, drone larva powder - the rest. The produced preparation can be stored up to two years.

EFFECT: group of inventions improves the biochemical blood values in animals, increases red blood cell count and total resistance.

3 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the use of a metal of group 4 or 5 of the periodic system specified in titanium, zirconium, hafnium, niobium and tantalum, or its oxide for preparing a drug used for treating or preventing a disease characterised by undesired expression and/or release of interferon-γ inducible protein of weight 10 kDa, IP-10 in a subject. The invention also refers to a method of treating or preventing the disease characterised by undesired expression and/or release of interferon-γ inducible protein of weight 10 kDa, IP-10, which implies the extraction of a biological fluid in a subject suffering said disease, the ex vivo contact of the biological fluid and the metal specified in titanium, zirconium, hafnium, niobium and tantalum, or its oxide, the fluid return after the contact with the metal to the subject stated above. The invention also provides the use of the method stated above or its oxide for the in vitro removal of interferon-γ inducible protein of weight 10 kDa, and a method for removing said protein. The invention also refers to a device for biological fluid purification which comprises a purification chamber with a fluid inlet and outlet and containing metal particles specified in titanium, zirconium, hafnium, niobium and tantalum, or its oxide, used for biological fluid purification, and a filter coupled with the fluid inlet and outlet to prevent said particles from escaping from the purification chamber.

EFFECT: invention provides the selective decrease of expression and release of chemokine, namely interferon-γ inducible protein of weight 10 kDa, IP-10.

25 cl, 6 tbl, 16 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. What is offered is an antioxidant and immunostimulating composition containing quantitatively (wt %): mexidol - 30, lithium ascorbate - 45 and litonit - 25.

EFFECT: invention provides producing the low-toxic preparation showing high antioxidant activity combined with immunostimulating properties.

1 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to coloproctology and deals with treatment of pilonidal cyst. Method includes excision of pilonidal cyst, bringing wound edges to wound bottom and partial suturing of wound with single "П"-shaped sutures without tension, carrying out antibiotic therapy. Before bringing wound edges to wound bottom on its lateral surface from the side of subcutaneous adipose cellular tissue made are 0.5 cm deep linear cuts along entire wound length at the distance 0.5 cm from the skin surface. At the distance 1.0-1.5 cm from post-operative wound edges at the level of wound bottom symmetrically from two sides installed are polychlorvinyl tubes equal in length to the wound length, with holes on the lateral surface, located in each 2 cm. In order to carry out immunotherapy, patient's blood is sampled, its cell masses are separated by centrifugation. Erythrocyte mass is returned to patient. Remaining cell mass is cultivated with 500000 U of interleukin-2 for 60 minutes at temperature 37°C, centrifuged with separation of supernatant fluid. Supernatant fluid, which contains complex of autologous cytokines, is introduced through tubes in volume 5 ml per each 2 cm of wound length on the first and third day after operation.

EFFECT: method ensures adequate immune sanitation of post-operative wound area, reducing risk of formation of cavities of wound edges and necrosis of wound edges.

2 cl, 3 dwg, 1 ex

FIELD: medicine, immunology.

SUBSTANCE: group of inventions relates to medicine in particular to immunology and can be applied to enhance the immune response of animals and human to antigen consisting of one or a number of epitopes; for the above purpose the parenteral immunization of the patient is performed either with the mixture of the above antigen and adjuvant in the shape of spherical particles or with the above antigen fixed on the surface of the spherical particles; at that the spherical particles consist of thermo-denaturated coat protein of spiral plant viruses, predominantly tobacco mosaic virus.

EFFECT: invention secures the efficient stimulation of the immune response to the antigen upon pareneteral immunization of the patient with small doses of the antigen.

2 cl, 9 ex, 9 dwg

FIELD: biology, medicine, nanotechnology.

SUBSTANCE: group of inventions is referred to the area of biology, medicine, nanotechnology and involves processing of new platform carriers for formation of complexes with biologically active compounds. The proposed platform carriers are of spherical shape and are made by the way of thermal reconfiguration of structure of tobacco mosaic virus (TMV) or another tobamovirus or another plant virus with spiral structure or their fragments. The platform carriers are also produced by the way of thermal reconfiguration of coat protein of TMV group virus (tobamoviruses) or another phytovirus with spiral structure or their fragments. There were also proposed the compositions containing the platform-carrier of said spherical carrier connected with the alien protein or another biologically active compound. The advantages of new platform carriers include the simplicity and quickness of production, possibility to get spherical particles of regulated sizes, long term storage, absence of aggregation and preservation of spherical shape during its storage, centrifugation and resedimentation, the convenience of spherical particles shape for formation of complexes with target compound.

EFFECT: important feature of a new carrier platform is the capability to adsorb on the surface and to form compositions with different structurally and functionally alien proteins/antigens.

3 cl, 6 ex, 10 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly oncology, and may be applied in treating lung cancer. In an operation room, immediately before the introduction to general anaesthesia, blood is taken from a patient suffering lung cancer in the amount of 200-300 ml is a sterile container with a haemo-preserving agent and separated; cell mass is selected and combined with carboplatin 150 mg/m2 and etoposide 100 mg/m2 in a first bottle. Formed plasma is combined with rhoncoleukin 1 mil. IU, incubated at 37°C for 30 minutes in a second bottle. It is followed by the intravenous drop-by-drop introduction of the content of the first bottle, and then of the second bottle. The lung operation for the removal of a malignant growth is completed conventionally.

EFFECT: method allows avoiding side toxic responses on the introduction of the cytostatics, performing the one-stage operating removal of the malignant growth with the introduction of the anti-cancer preparations and improving body resistance, preventing postoperative complications.

4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used in practice of physicians, immunologists, infectious disease specialists, rehabilitation specialists. Method includes application of immunomodulator of natural origin with additional administration of procedures by programme of resonance-acoustic fluctuations (PIAF), radon-containing mineral baths, procedures in halochamber and mini-sauna "Cedar barrel". Also performed is intestinal lavage. Course is carried out during 14 days at the background of diet therapy.

EFFECT: method ensures complex immunorehabilitation with adequate activation of cell and humoral immunity, reduction of inflammation, achievement of immune system balance, self-regulation, improvement of functional adaptive and protective possibilities of organism, relieving emotional stress.

5 cl, 2 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes a system of carrier microparticles containing one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other biologically active substances with or without attached target molecules. The invention describes immunomodulatory compounds for induction of an immunomodulatory effect - protective immunity and tolerance. The immunobiologically active compound contains a pathogen-associated molecular structure and a carrier in the form of agarose microparticles. The molecular structure represents at least an immunobiologically active antigen and an antigen epitope with the antigen epitope is a peptide, a protein, a recombinant peptide or a multipeptide, a lipid, a carbohydrate, a nucleic acid or their combinations. There are described methods for identifying the immunobiologically active peptides for preparing the immunobiologically active compounds and methods for inducing a tolerant immune response and enhancing immunity with the use of the compounds described in the invention.

EFFECT: invention provides stable compounds with the wide range of immunogens and target molecules enables stimulating protective immunity and tolerance in both infected, and non-infected hosts.

52 cl, 5 dwg, 4 tbl, 34 ex

FIELD: medicine.

SUBSTANCE: method involves the intramuscular introduction of the preparations Galavite 200 mcg/mouse and Lidocaine 8 mcg/kg of body weight once a day for three days running every 24 hours to experimental animals CBA line mice suffering a burning injury with underlying mycotic and bacterial infections accompanied by anti-infectious protection suppression.

EFFECT: invention enables creating a model of hospital strain formation which is applicable for studying the variations of the properties of opportunistic microorganisms to increasing virulence and antibiotic resistance.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely pediatrics, may be used for preventing influenza and acute respiratory infections in children suffering bronchial asthma. For this purpose, 5 days before the scheduled influenza vaccination, Viferon is introduced in a child's body through rectum in the form of suppositories twice a day in the morning and in the evening, one suppository in a single dose for children aged 4 to 7 years old 150000 ME, 7 to 16 years - 500000 ME, and the second stage involves introducing the inactivated influenza vaccine.

EFFECT: use of the given method allows improving a clinical course of the post-vaccinal period ensured by reducing intercurrent ARIs in 4 times, and also decreasing the rate of influenza and ARIs of the other aetiology for the following epidemiological period in 2 times.

2 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chelated mercury complexes with cysteine of formula C6H13O4N2S2HgCl or methionine of formula C10H21O4N2S2HgCl which show anticancer, antiviral, antiparasitic and immunomodulating action. The invention also concerns a method for preparing the complexes specified above which involves conducting a reaction of mercury dichloride and an aqueous solution of cysteine or methionine, keeping the mixture at temperature 35-40°C for 60-90 min, cooling the reaction mixture to 18-20°C and setting at this temperature for one day. The invention also refers to a drug preparation that is an apoptosis modulator of showing anticancer, antiviral, immunomodulating and antiparasitic action which contains the chelated mercury complex with cysteine or methionine 0.38-0.52 wt % and distilled water.

EFFECT: invention provides preparing the new chelated mercury complexes showing anticancer, antiviral, antiparasitic and immunomodulating action, and also the simplified method for preparing them at lower temperatures.

6 cl, 8 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to an amine compound of formula (I), pharmaceutically acceptable addition salts, hydrates or solvates thereof, having immunodepressive effect , where R - H or P(=O)(OH)2; X - O or S; Y denotes -CH2CH2- or -CH=CH-; Z denotes C1-5-alkylene, C2-5-alkenylene or C2-5-alkynylene; R1 denotes CF3, R2 denotes C1-4-alkyl, substituted with OH or halogen; R3 and R4 independently denotes H < or C1-4-alkyl; A denotes optionally substituted C6-10-aryl, heteroaryl containing 5-10 ring atoms, where 1 or 2 atoms are selected from N, O and S, C3-7-cycloalkyl optionally condensed with optionally substituted benzene, or heterocycloalkyl containing 5-7 ring atoms, where 1 or 2 atoms are selected from N and O, where said substitutes are selected from C1-4-alkylthio, C1-4-alkylsulphanyl, C1-4-alkylsulphonyl, C2-5-alkylcarbonyl, halogen, cyano, nitro, C3-7-cycloalkyl, C6-10-aryl, C7-14-aralkyloxy, C6-10-aryloxy, optionally substituted with oxo or halogen, C2-3-alkyleneoxy, C3-4-alkylene or C1-2-alkylenedioxy, optionally substituted with halogen C1-4-alkyl or C1-4-alkoxy.

EFFECT: novel compound which is effective in reducing the level of lymphocytes in peripheral blood, suppresses tissue breakdown and exhibiting less side effects, such as bradycardia, is disclosed.

20 cl, 237 ex, 2 tbl

FIELD: food industry.

SUBSTANCE: invention relates to production of a biologically active food additive and may be used for preventive alimentation. Milled horseradish root is infused in water during no less than 24 hours at a ratio of S: L = 1: (4.5 -5.0). The water extract is subjected to vacuum sublimation dehydration. Produced sublimated horseradish root powder in an amount of 25-35 g is mixed with 900-1100 g of natural floral honey. One introduces (while thoroughly stirring) magnolia vine oil into the mixture in an amount of 35-45 drops per 1000 g of the mixture.

EFFECT: simple mixing of the initial components, in a strictly specified ratio without modification of their chemical composition allows to enhance efficiency of the biologically active food additive impact on the immune system and to strengthen antiviral activity.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology. Method includes intramuscular introduction of immunomodulating medication reaferon. Optimal starting dose of reaferon is selected individually for each patient. For this purpose method of electroacupuncture diagnostics by R.Voll is used. Testing of information-wave markers of human body temperature 37.5 and 38.0 degrees Celcius and reaferon doses in 1, 2, 3 and more mln UNITS is carried out. Testing is performed separately on control points of measurement of meridians of lymphatic system, nerve degeneration, blood circulation, epithelial and parenchymatous degeneration, allergy, triple heater. After that selected is such dose of reaferon during combined, simultaneous testing of which with information-wave markers of human body temperature 37.5 and 38.0 degrees Celcius, indices of scale of apparatus for electroacupuncture diagnostics by R.Voll equal 50-60 conventional units of measurement.

EFFECT: method improves treatment efficiency due to reduction of side effects and complications.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics. A composition contains nanosized silver powder, nanosized aluminium powder and nanosized diamond powder in the following proportions, wt %: nanosized silver powder - 40, aluminium powder -30, nanosized diamond powder -30.

EFFECT: composition shows a combined immunomodulatory and antibacterial effect, low toxicity.

3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmacology, and represents the use of a pharmaceutically acceptable salt of alpha-ketoglutaric acid for preparing a pharmaceutical composition for treatment or prevention of cartilage diseases in response to weight loss and/or nutritional disorder, poor nutrition, gastrectomy, partial gastrectomy or gastric ligation.

EFFECT: invention provides effective relief and management of articular pain and arthritis.

20 cl, 8 tbl, 3 dwg

Up!